Show simple item record

dc.contributor.authorAlexander, JL
dc.contributor.authorPosma, JM
dc.contributor.authorScott, A
dc.contributor.authorPoynter, L
dc.contributor.authorMason, SE
dc.contributor.authorDoria, ML
dc.contributor.authorHerendi, L
dc.contributor.authorRoberts, L
dc.contributor.authorMcDonald, JAK
dc.contributor.authorCameron, S
dc.contributor.authorHughes, DJ
dc.contributor.authorLiska, V
dc.contributor.authorSusova, S
dc.contributor.authorSoucek, P
dc.contributor.authorder Sluis, VH-V
dc.contributor.authorGomez-Romero, M
dc.contributor.authorLewis, MR
dc.contributor.authorHoyles, L
dc.contributor.authorWoolston, A
dc.contributor.authorCunningham, D
dc.contributor.authorDarzi, A
dc.contributor.authorGerlinger, M
dc.contributor.authorGoldin, R
dc.contributor.authorTakats, Z
dc.contributor.authorMarchesi, JR
dc.contributor.authorTeare, J
dc.contributor.authorKinross, J
dc.coverage.spatialEngland
dc.date.accessioned2023-08-01T15:01:12Z
dc.date.available2023-08-01T15:01:12Z
dc.date.issued2023-05-08
dc.identifierARTN 100
dc.identifier10.1186/s40168-023-01518-w
dc.identifier.citationMicrobiome, 2023, 11 (1), pp. 100 -
dc.identifier.issn2049-2618
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5919
dc.identifier.eissn2049-2618
dc.identifier.eissn2049-2618
dc.identifier.doi10.1186/s40168-023-01518-w
dc.description.abstractBACKGROUND AND AIMS: The gut microbiota is implicated in the pathogenesis of colorectal cancer (CRC). We aimed to map the CRC mucosal microbiota and metabolome and define the influence of the tumoral microbiota on oncological outcomes. METHODS: A multicentre, prospective observational study was conducted of CRC patients undergoing primary surgical resection in the UK (n = 74) and Czech Republic (n = 61). Analysis was performed using metataxonomics, ultra-performance liquid chromatography-mass spectrometry (UPLC-MS), targeted bacterial qPCR and tumour exome sequencing. Hierarchical clustering accounting for clinical and oncological covariates was performed to identify clusters of bacteria and metabolites linked to CRC. Cox proportional hazards regression was used to ascertain clusters associated with disease-free survival over median follow-up of 50 months. RESULTS: Thirteen mucosal microbiota clusters were identified, of which five were significantly different between tumour and paired normal mucosa. Cluster 7, containing the pathobionts Fusobacterium nucleatum and Granulicatella adiacens, was strongly associated with CRC (PFDR = 0.0002). Additionally, tumoral dominance of cluster 7 independently predicted favourable disease-free survival (adjusted p = 0.031). Cluster 1, containing Faecalibacterium prausnitzii and Ruminococcus gnavus, was negatively associated with cancer (PFDR = 0.0009), and abundance was independently predictive of worse disease-free survival (adjusted p = 0.0009). UPLC-MS analysis revealed two major metabolic (Met) clusters. Met 1, composed of medium chain (MCFA), long-chain (LCFA) and very long-chain (VLCFA) fatty acid species, ceramides and lysophospholipids, was negatively associated with CRC (PFDR = 2.61 × 10-11); Met 2, composed of phosphatidylcholine species, nucleosides and amino acids, was strongly associated with CRC (PFDR = 1.30 × 10-12), but metabolite clusters were not associated with disease-free survival (p = 0.358). An association was identified between Met 1 and DNA mismatch-repair deficiency (p = 0.005). FBXW7 mutations were only found in cancers predominant in microbiota cluster 7. CONCLUSIONS: Networks of pathobionts in the tumour mucosal niche are associated with tumour mutation and metabolic subtypes and predict favourable outcome following CRC resection. Video Abstract.
dc.formatElectronic
dc.format.extent100 -
dc.languageeng
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofMicrobiome
dc.rights.urihttps://creativecommons.org/publicdomain/zero/1.0/
dc.subjectColorectal cancer
dc.subjectGut microbiota
dc.subjectMetabolome
dc.subjectMetataxonomics
dc.subjectHumans
dc.subjectChromatography, Liquid
dc.subjectTandem Mass Spectrometry
dc.subjectMicrobiota
dc.subjectGastrointestinal Microbiome
dc.subjectColorectal Neoplasms
dc.titlePathobionts in the tumour microbiota predict survival following resection for colorectal cancer.
dc.typeJournal Article
dcterms.dateAccepted2023-03-15
dc.date.updated2023-08-01T15:00:50Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1186/s40168-023-01518-w
rioxxterms.licenseref.startdate2023-05-08
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37158960
pubs.issue1
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Translational Oncogenomics
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/ImmNet
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1186/s40168-023-01518-w
pubs.volume11
icr.researchteamMedicine (RMH)
icr.researchteamTransl Oncogenomics
dc.contributor.icrauthorGerlinger, Marco
icr.provenanceDeposited by Mr Arek Surman (impersonating Prof Richard Houlston) on 2023-08-01. Deposit type is initial. No. of files: 1. Files: Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/publicdomain/zero/1.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/publicdomain/zero/1.0/